BIOCELTIX S.A. ZY -10 (XI3) - Total Liabilities
Based on the latest financial reports, BIOCELTIX S.A. ZY -10 (XI3) has total liabilities worth €2.36 Million EUR (≈ $2.75 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See working capital to net assets of BIOCELTIX S.A. ZY -10 to evaluate short-term liquidity relative to the company's equity base.
BIOCELTIX S.A. ZY -10 - Total Liabilities Trend (2021–2025)
This chart illustrates how BIOCELTIX S.A. ZY -10's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see BIOCELTIX S.A. ZY -10 total assets.
BIOCELTIX S.A. ZY -10 Competitors by Total Liabilities
The table below lists competitors of BIOCELTIX S.A. ZY -10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Infant Bacterial Therapeutics AB (publ)
ST:IBT-B
|
Sweden | Skr53.87 Million |
|
Engtex Group Bhd
KLSE:5056
|
Malaysia | RM745.19 Million |
|
Maeil Holdings Co. Ltd
KQ:005990
|
Korea | ₩567.53 Billion |
|
Gigante Salmon AS
OL:GIGA
|
Norway | Nkr610.38 Million |
|
Zevia Pbc
NYSE:ZVIA
|
USA | $24.21 Million |
|
Pearson PLC
LSE:PSON
|
UK | GBX2.79 Billion |
|
Maxiparts Ltd
AU:MXI
|
Australia | AU$97.45 Million |
|
CURATIS N AG
SW:CURN
|
Switzerland | CHF9.96 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down BIOCELTIX S.A. ZY -10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See XI3 net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 32.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIOCELTIX S.A. ZY -10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIOCELTIX S.A. ZY -10 (2021–2025)
The table below shows the annual total liabilities of BIOCELTIX S.A. ZY -10 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.36 Million ≈ $2.75 Million |
-31.46% |
| 2024-12-31 | €3.44 Million ≈ $4.02 Million |
+51.47% |
| 2023-12-31 | €2.27 Million ≈ $2.65 Million |
-9.35% |
| 2022-12-31 | €2.50 Million ≈ $2.93 Million |
+13.93% |
| 2021-12-31 | €2.20 Million ≈ $2.57 Million |
-- |
About BIOCELTIX S.A. ZY -10
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells … Read more